PulseAugur
EN
LIVE 21:16:14
中文(ZH) 汇宇制药：注射用HY07121（皮下注射）临床试验申请获受理

Huayu Pharmaceutical's novel triple-target cancer therapy gains clinical trial approval

By PulseAugur Editorial · [1 sources] ·

Huayu Pharmaceutical's subsidiary, Huayu Haiyue, has received approval from China's National Medical Products Administration to begin clinical trials for HY07121, a novel subcutaneous injection for advanced solid tumors. This innovative biologic is a triple-target fusion protein designed to combat PD-1, TIGIT, and IL-15/IL-15Rα, aiming to enhance patient convenience and reduce side effects. Currently, no other triple-target products are available on the market. AI

IMPACT This development signifies progress in targeted cancer therapies, potentially offering new treatment options with improved patient outcomes.

RANK_REASON The cluster reports on the acceptance of a clinical trial application for a new biologic drug, which falls under research and development in the pharmaceutical industry. [lever_c_demoted from research: ic=1 ai=0.4]

Read on 36氪 (36Kr) →

AI-generated summary · Google Gemini · from 1 sources. How we write summaries →

Huayu Pharmaceutical's novel triple-target cancer therapy gains clinical trial approval

How we ranked this

Signal score
0 / 100
Composite score across the factors below. Higher = stronger signal that this story matters right now.
Newsworthiness bucket
Tool
The cluster reports on the acceptance of a clinical trial application for a new biologic drug, which falls under research and development in the pharmaceutical industry. [lever_c_demoted from resea…
Source corroboration
Single-source cluster
Only one publisher covered this so far. Single-source stories can still rank when the publisher is high-authority, but they lack cross-source corroboration.
Topics
product, paper
Editorial topic classification. Feeds into how the story surfaces on /topic/<slug> hub pages and into the per-entity coverage mix.
AI-industry relevance
Standard
On-topic for AI-industry coverage; kept in the public index.
Story freshness
103 days old
Aged out of breaking-news scoring windows; ranking reflects the durable signal from the full source set.

Full methodology in our editorial standards.

COVERAGE [1]

  1. 36氪 (36Kr) TIER_1 中文(ZH) ·

    Huiyu Pharmaceutical: Clinical Trial Application for Injectable HY07121 (Subcutaneous Injection) Accepted

    36氪获悉，汇宇制药公告，公司全资子公司汇宇海玥收到国家药监局核准签发的《受理通知书》，注射用HY07121(皮下注射)用于治疗晚期实体瘤的临床试验申请获得受理。该药品为自主研发的抗PD-1、抗TIGIT、IL-15/IL-15Rα双抗融合蛋白，属1类创新型治疗用生物制品，旨在提高患者便利性并减少副作用。截至公告日，尚无同类三靶点产品上市。

RELATED TOPICS